OraSure (OSUR) Technologies submitted two separate applications at the end of 2025 to the U.S. Food and Drug Administration for clearance of its rapid molecular self-test for Chlamydia trachomatis and ...
BETHLEHEM, Pa., Jan. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (OSUR) (“OraSure” and “OTI”), a leader in point-of-need and home diagnostic tests and sample management solutions, today ...
OraSure TechnologiesOSUR recently announced that it submitted two applications to the FDA seeking approval for its two new at-home tests for sexually transmitted infections (STIs), aiming to expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results